TWI876835B - B-raf激酶抑制劑的馬來酸鹽、其結晶形式及用途 - Google Patents

B-raf激酶抑制劑的馬來酸鹽、其結晶形式及用途 Download PDF

Info

Publication number
TWI876835B
TWI876835B TW113101605A TW113101605A TWI876835B TW I876835 B TWI876835 B TW I876835B TW 113101605 A TW113101605 A TW 113101605A TW 113101605 A TW113101605 A TW 113101605A TW I876835 B TWI876835 B TW I876835B
Authority
TW
Taiwan
Prior art keywords
compound
cancer
crystalline form
dihydro
maleate
Prior art date
Application number
TW113101605A
Other languages
English (en)
Chinese (zh)
Other versions
TW202434587A (zh
Inventor
張國良
昌友 周
Original Assignee
英屬開曼群島商百濟神州有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英屬開曼群島商百濟神州有限公司 filed Critical 英屬開曼群島商百濟神州有限公司
Publication of TW202434587A publication Critical patent/TW202434587A/zh
Application granted granted Critical
Publication of TWI876835B publication Critical patent/TWI876835B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
TW113101605A 2015-04-15 2016-04-14 B-raf激酶抑制劑的馬來酸鹽、其結晶形式及用途 TWI876835B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2015/076639 2015-04-15
CN2015076639 2015-04-15

Publications (2)

Publication Number Publication Date
TW202434587A TW202434587A (zh) 2024-09-01
TWI876835B true TWI876835B (zh) 2025-03-11

Family

ID=57125563

Family Applications (4)

Application Number Title Priority Date Filing Date
TW113101605A TWI876835B (zh) 2015-04-15 2016-04-14 B-raf激酶抑制劑的馬來酸鹽、其結晶形式及用途
TW110125410A TWI792406B (zh) 2015-04-15 2016-04-14 B-raf激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途
TW112101259A TWI832668B (zh) 2015-04-15 2016-04-14 Ｂ-ｒａｆ激酶抑制劑的無定形形式、鹽酸鹽、甲磺酸鹽、２-羥基乙磺酸鹽、ｌ-酒石酸鹽或草酸鹽及其用途
TW105111715A TWI736531B (zh) 2015-04-15 2016-04-14 B-raf 激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW110125410A TWI792406B (zh) 2015-04-15 2016-04-14 B-raf激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途
TW112101259A TWI832668B (zh) 2015-04-15 2016-04-14 Ｂ-ｒａｆ激酶抑制劑的無定形形式、鹽酸鹽、甲磺酸鹽、２-羥基乙磺酸鹽、ｌ-酒石酸鹽或草酸鹽及其用途
TW105111715A TWI736531B (zh) 2015-04-15 2016-04-14 B-raf 激酶抑制劑的馬來酸鹽、其結晶形式、製備方法及用途

Country Status (15)

Country Link
US (1) US10351559B2 (OSRAM)
EP (2) EP4119559A1 (OSRAM)
JP (3) JP7320741B2 (OSRAM)
KR (2) KR102643609B1 (OSRAM)
CN (2) CN107531682B (OSRAM)
AU (1) AU2016248376B2 (OSRAM)
CA (1) CA2981746C (OSRAM)
EA (1) EA035680B1 (OSRAM)
IL (2) IL255555B (OSRAM)
MX (1) MX381053B (OSRAM)
NZ (1) NZ735715A (OSRAM)
SG (1) SG11201707984TA (OSRAM)
TW (4) TWI876835B (OSRAM)
WO (1) WO2016165626A1 (OSRAM)
ZA (1) ZA201706392B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
JP5885670B2 (ja) 2009-12-11 2016-03-15 アルデイラ セラピューティクス， インコーポレイテッド 黄斑変性の処置のための組成物および方法
EP3124472B1 (en) 2011-12-31 2018-07-25 BeiGene, Ltd. Fused tricyclic compounds as raf kinase inhibitors
JP6514114B2 (ja) 2013-01-23 2019-05-15 アルデイラ セラピューティクス， インコーポレイテッド 毒性アルデヒド関連疾患および処置
CN107531682B (zh) * 2015-04-15 2021-05-04 百济神州有限公司 B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
CN110494166B (zh) 2017-05-02 2022-11-08 诺华股份有限公司 组合疗法
EP3694500A4 (en) 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
LT3873894T (lt) * 2018-10-31 2023-06-26 Les Laboratoires Servier Naujoji bcl-2 inhibitoriaus druska, susijusi kristalinė forma, jos gamybos būdas ir farmacinės kompozicijos, kurių sudėtyje ji yra
CN111484488A (zh) * 2019-01-25 2020-08-04 百济神州(北京)生物科技有限公司 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
CN111484489B (zh) * 2019-01-25 2023-05-23 百济神州(北京)生物科技有限公司 无定形的b-raf激酶二聚体抑制剂
BR112021016921A2 (pt) * 2019-03-15 2021-11-03 Forma Therapeutics Inc Inibição de proteína de ligação a elemento responsivo a amp cíclico (creb)
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
BR112021022335A2 (pt) 2019-05-13 2021-12-28 Novartis Ag Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
CN111184693B (zh) * 2019-05-29 2023-07-21 百济神州(苏州)生物科技有限公司 一种raf激酶抑制剂制剂及其制备方法
KR20230048476A (ko) * 2020-04-03 2023-04-11 베이진 리미티드 암 치료 시에 사용하기 위한 미르다메티닙과 리피라페닙의 공동 투여
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2023240178A1 (en) * 2022-06-08 2023-12-14 Mapkure, Llc Methods of treating cancer with a b-raf inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097224A1 (en) * 2011-12-31 2013-07-04 Beigene, Ltd. Fused tricyclic compounds as raf kinase inhibitors
CN103476770A (zh) * 2010-11-25 2013-12-25 拉蒂欧制药有限责任公司 新的阿法替尼盐和多晶型物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5111113B2 (ja) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
BRPI0619514A2 (pt) * 2005-12-08 2011-10-04 Millennium Pharm Inc compostos bicìclicos com atividade inibidora cinase, composição farmacêutica contendo os mesmos e uso de ditos compostos
WO2007136572A2 (en) 2006-05-15 2007-11-29 Merck & Co., Inc. Antidiabetic bicyclic compounds
EP2057141B1 (en) 2006-08-23 2011-10-26 Pfizer Products Inc. Pyrimidone compounds as gsk-3 inhibitors
WO2008030448A1 (en) 2006-09-07 2008-03-13 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
KR20090130345A (ko) 2007-05-04 2009-12-22 아이알엠 엘엘씨 Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 화합물 및 조성물
US20100197924A1 (en) * 2008-12-22 2010-08-05 Millennium Pharmaceuticals, Inc. Preparation of aminotetralin compounds
CN107531682B (zh) 2015-04-15 2021-05-04 百济神州有限公司 B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476770A (zh) * 2010-11-25 2013-12-25 拉蒂欧制药有限责任公司 新的阿法替尼盐和多晶型物
WO2013097224A1 (en) * 2011-12-31 2013-07-04 Beigene, Ltd. Fused tricyclic compounds as raf kinase inhibitors

Also Published As

Publication number Publication date
IL287740B2 (en) 2025-11-01
CA2981746C (en) 2023-08-01
EA035680B1 (ru) 2020-07-24
TW202138370A (zh) 2021-10-16
IL255555B (en) 2021-12-01
WO2016165626A1 (en) 2016-10-20
JP2024012540A (ja) 2024-01-30
US10351559B2 (en) 2019-07-16
EA201792254A1 (ru) 2018-02-28
TWI792406B (zh) 2023-02-11
MX381053B (es) 2025-03-12
ZA201706392B (en) 2019-05-29
EP3283486A1 (en) 2018-02-21
TW202330526A (zh) 2023-08-01
CN107531682A (zh) 2018-01-02
KR20170139073A (ko) 2017-12-18
TWI736531B (zh) 2021-08-21
JP7383652B2 (ja) 2023-11-20
KR20240049684A (ko) 2024-04-16
TW202434587A (zh) 2024-09-01
TW201702241A (zh) 2017-01-16
KR102643609B1 (ko) 2024-03-05
MX2017013219A (es) 2018-02-15
JP2021073246A (ja) 2021-05-13
EP3283486A4 (en) 2018-08-22
CN107531682B (zh) 2021-05-04
IL255555A (en) 2018-01-31
EP3283486B1 (en) 2022-07-27
EP4119559A1 (en) 2023-01-18
JP7320741B2 (ja) 2023-08-04
CN113307805A (zh) 2021-08-27
US20180127412A1 (en) 2018-05-10
IL287740B1 (en) 2025-07-01
SG11201707984TA (en) 2017-11-29
IL287740A (en) 2021-12-01
CA2981746A1 (en) 2016-10-20
TWI832668B (zh) 2024-02-11
AU2016248376A1 (en) 2017-10-12
NZ735715A (en) 2022-09-30
AU2016248376B2 (en) 2020-10-08
JP2018511634A (ja) 2018-04-26
BR112017020945A2 (pt) 2018-07-10

Similar Documents

Publication Publication Date Title
TWI876835B (zh) B-raf激酶抑制劑的馬來酸鹽、其結晶形式及用途
CN110036007B (zh) 吡啶化合物
TWI826373B (zh) (s)-2-((2-((s)-4-(二氟甲基)-2-氧代唑烷-3-基)-5,6-二氫苯并[f]咪唑并[1,2-d][1,4]氧氮呯-9-基)胺基)丙醯胺之多晶型及固體形式及製造方法
TWI675839B (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
HK40049820A (en) Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
HK40084617A (en) Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
JP2016520625A (ja) イコチニブリン酸塩の新規な多形及びその使用
CN111892536A (zh) 取代的喹啉甲酰胺类化合物及其用途
TW202542122A (zh) 包含（５ｒ，６ｓ）—１０，１１—二氟—１２—（（２—氟—４—碘苯基）—５，６—二羥基—４，５，６，７—四氫—１１１—螺［苯并［ｂ］［１，５，４］氧雜噻西啶—３，１＇—環丙烷］２，２—二氧化物之固體形式以及包含其之組合物及使用其之方法
WO2025147497A1 (en) Solid forms comprising (5r,6s)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide, and compositions comprising and methods of using the same
BR112017020945B1 (pt) Sais cristalinos de sesqui-maleato de um inibidor de quinase b-raf, método e processo de preparação e usos dos mesmos
HK40020487B (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
TW201512203A (zh) 埃克替尼馬來酸鹽的晶型及其用途